Comparative Pharmacology
Head-to-head clinical analysis: EXBLIFEP versus ZOSYN IN PLASTIC CONTAINER.
Peer-Reviewed Evidence
Head-to-head clinical analysis: EXBLIFEP versus ZOSYN IN PLASTIC CONTAINER.
EXBLIFEP vs ZOSYN IN PLASTIC CONTAINER
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Exblifep is a beta-lactamase inhibitor combination consisting of cefepime, a cephalosporin antibacterial, and enmetazobactam, a beta-lactamase inhibitor. Enmetazobactam inhibits Ambler class A and some class C beta-lactamases, restoring cefepime activity against beta-lactamase-producing Enterobacterales.
Piperacillin, a ureidopenicillin, inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), inhibiting transpeptidation and autolysin inhibitors. Tazobactam, a beta-lactamase inhibitor, irreversibly inactivates beta-lactamases, preventing hydrolysis of piperacillin.
2.5 g (cefepime 2 g, enmetazobactam 0.5 g) intravenously every 8 hours infused over 2 hours.
3.375 g (piperacillin 3 g + tazobactam 0.375 g) intravenously every 6 hours over 30 minutes. For nosocomial pneumonia, 4.5 g every 6 hours.
None Documented
None Documented
The terminal elimination half-life of Exblifep is approximately 8-10 hours in patients with normal renal function. In patients with renal impairment, half-life is prolonged and dosing adjustments are required.
Piperacillin: 0.7-1.2 hours (normal renal function). Tazobactam: 0.7-0.9 hours. Clinically, half-life extends to 2-6 hours in renal impairment (CrCl <20 mL/min); requires dose adjustment.
Exblifep is primarily excreted renally as unchanged drug (approximately 60-70% of the dose) and as the active metabolite nifepristone (approximately 20-30%). Fecal excretion accounts for <10% of the dose. Biliary excretion is minimal.
Piperacillin: ~68% renal (glomerular filtration and tubular secretion), 9-17% biliary. Tazobactam: ~80% renal (unchanged and inactive metabolite). Mean cumulative urinary recovery: piperacillin 68%, tazobactam 80%; fecal recovery: piperacillin ~11%, tazobactam <1%.
Category C
Category C
Antibiotic
Antibiotic